Form 8-K - Current report:
SEC Accession No. 0001640334-25-000192
Filing Date
2025-02-05
Accepted
2025-02-05 16:45:09
Documents
19
Period of Report
2025-02-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K lxrp_8k.htm   iXBRL 8-K 33155
2 OPINION lxrp_ex51.htm EX-5.1 13461
3 SALES AGREEMENT lxrp_ex101.htm EX-10.1 11119
9 lxrp_ex51img2.jpg GRAPHIC 6334
10 lxrp_ex51img1.jpg GRAPHIC 6334
  Complete submission text file 0001640334-25-000192.txt   223817

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20250205.xsd EX-101.SCH 6102
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20250205_lab.xml EX-101.LAB 16261
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20250205_cal.xml EX-101.CAL 898
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20250205_pre.xml EX-101.PRE 11938
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20250205_def.xml EX-101.DEF 4194
21 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_8k_htm.xml XML 5586
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 8-K | Act: 34 | File No.: 001-39874 | Film No.: 25593986
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)